LYmphoid NeXt-Generation Sequencing (LYNX) Panel A Comprehensive Capture-Based Sequencing Tool for the Analysis of Prognostic and Predictive Markers in Lymphoid Malignancies

Warning

This publication doesn't include Faculty of Sports Studies. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	NAVRKALOVÁ Veronika PLEVOVÁ Karla HYNŠT Jakub PÁL Karol MAREČKOVÁ Andrea REIGL Tomáš JELÍNKOVÁ Hana VRZALOVÁ Zuzana STRÁNSKÁ Kamila PAVLOVÁ Šárka PANOVSKÁ Anna JANÍKOVÁ Andrea DOUBEK Michael KOTAŠKOVÁ Jana POSPÍŠILOVÁ Šárka
Year of publication	2021
Type	Article in Periodical
Magazine / Source	The journal of molecular diagnostics.
MU Faculty or unit	Central European Institute of Technology
Citation
Web	https://www.sciencedirect.com/science/article/pii/S1525157821001343?via%3Dihub
Doi	http://dx.doi.org/10.1016/j.jmoldx.2021.05.007
Keywords	LYNX; Lymphoid Malignancies; Prognostic and Predictive Markers
Description	B-cell neoplasms represent a clinically heterogeneous group of hematologic malignancies with considerably diverse genomic architecture recently endorsed by next-generation sequencing (NGS) studies. Because multiple genetic defects have a potential or confirmed clinical impact, a tendency toward more comprehensive testing of diagnostic, prognostic, and predictive markers is desired. This study introduces the design, validation, and implementation of an integrative, custom-designed, capture-based NGS panel titled LYmphoid NeXt-generation sequencing (LYNX) for the analysis of standard and novel molecular markers in the most common lymphoid neoplasms (chronic lymphocytic leukemia, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma). A single LYNX test provides the following: i) accurate detection of mutations in all coding exons and splice sites of 70 lymphoma-related genes with a sensitivity of 5% variant allele frequency, ii) reliable identification of large genome-wide (>6 Mb) and recurrent chromosomal aber-rations (>300 kb) in at least 20% of the clonal cell fraction, iii) the assessment of immunoglobulin and T-cell receptor gene rearrangements, and iv) lymphoma-specific translocation detection. Dedicated bioinformatic pipelines were designed to detect all markers mentioned above. The LYNX panel repre-sents a comprehensive, up-to-date tool suitable for routine testing of lymphoid neoplasms with research and clinical applicability. It allows a wide adoption of capture-based targeted NGS in clinical practice and personalized management of patients with lymphoproliferative diseases.
Related projects:	e-Infrastruktura CZ